HK1198279A1 - Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate - Google Patents
Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetateInfo
- Publication number
- HK1198279A1 HK1198279A1 HK14111812.7A HK14111812A HK1198279A1 HK 1198279 A1 HK1198279 A1 HK 1198279A1 HK 14111812 A HK14111812 A HK 14111812A HK 1198279 A1 HK1198279 A1 HK 1198279A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- laquinimod
- treatment
- combination
- multiple sclerosis
- glatiramer acetate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
- A61J1/035—Blister-type containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161512808P | 2011-07-28 | 2011-07-28 | |
| PCT/US2012/048684 WO2013016684A1 (en) | 2011-07-28 | 2012-07-27 | Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1198279A1 true HK1198279A1 (en) | 2015-03-27 |
Family
ID=47597714
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK14111812.7A HK1198279A1 (en) | 2011-07-28 | 2014-11-21 | Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate |
| HK16114575A HK1226940A1 (zh) | 2011-07-28 | 2016-12-22 | 用拉喹莫德與醋酸格拉替雷的組合治療多發性硬化症 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK16114575A HK1226940A1 (zh) | 2011-07-28 | 2016-12-22 | 用拉喹莫德與醋酸格拉替雷的組合治療多發性硬化症 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20130029916A1 (es) |
| EP (1) | EP2736335A4 (es) |
| JP (2) | JP2014521658A (es) |
| KR (1) | KR20140054166A (es) |
| CN (2) | CN105944081A (es) |
| AU (2) | AU2012286699A1 (es) |
| BR (1) | BR112014002095A2 (es) |
| CA (1) | CA2843433A1 (es) |
| CL (2) | CL2014000209A1 (es) |
| EA (1) | EA201490377A1 (es) |
| HK (2) | HK1198279A1 (es) |
| IL (1) | IL251397A0 (es) |
| IN (1) | IN2014MN00333A (es) |
| MX (1) | MX2014001050A (es) |
| PE (1) | PE20142319A1 (es) |
| SG (1) | SG10201606191PA (es) |
| UY (1) | UY34358A (es) |
| WO (1) | WO2013016684A1 (es) |
| ZA (1) | ZA201401371B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2977049A1 (en) | 2007-12-20 | 2016-01-27 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
| SG10201501535UA (en) * | 2010-03-03 | 2015-04-29 | Teva Pharma | Treatment of lupus nephritis using laquinimod |
| PT2542079E (pt) | 2010-03-03 | 2014-07-18 | Teva Pharma | Tratamento da artrite reumatoide com uma combinação de laquinimod e metotrexato |
| CN103974704A (zh) | 2011-10-12 | 2014-08-06 | 泰华制药工业有限公司 | 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症 |
| KR20140138694A (ko) | 2012-02-03 | 2014-12-04 | 테바 파마슈티컬 인더스트리즈 리미티드 | 최선의 항-TNFα 요법에 실패한 크론병 환자를 치료하기 위한 라퀴니모드의 용도 |
| CN104114172A (zh) | 2012-02-16 | 2014-10-22 | 泰华制药工业有限公司 | N-乙基-n-苯基-1,2-二氢-4,5-二-羟基-1-甲基-2-氧代-3-喹啉甲酰胺、其制备和用途 |
| TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺 |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| CA2890194A1 (en) | 2012-11-07 | 2014-05-15 | Teva Pharmaceutical Industries Ltd. | Amine salts of laquinimod |
| US20160046582A1 (en) | 2013-03-14 | 2016-02-18 | Teva Pharmaceutical Industries Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| WO2015038963A1 (en) * | 2013-09-12 | 2015-03-19 | Teva Pharmaceutical Industries, Ltd. | Gene expression biomarkers of laquinimod responsiveness |
| KR20160085757A (ko) * | 2013-09-27 | 2016-07-18 | 테바 파마슈티컬 인더스트리즈 리미티드 | 다발성 경화증의 치료를 위한 라퀴니모드 병용 치료 |
| EP3068395A4 (en) * | 2013-11-15 | 2017-07-12 | Teva Pharmaceutical Industries Ltd. | Treatment of glaucoma using laquinimod |
| EP3094330A4 (en) * | 2014-01-17 | 2017-09-27 | Teva Pharmaceutical Industries Ltd | Treatment of crohn's disease using low doses of laquinimod |
| AU2015253330A1 (en) | 2014-04-29 | 2016-12-01 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status |
| US20150361757A1 (en) * | 2014-06-17 | 2015-12-17 | Baker Hughes Incoporated | Borehole shut-in system with pressure interrogation for non-penetrated borehole barriers |
| CA2961187A1 (en) * | 2014-09-16 | 2016-03-24 | Teva Pharmaceuticals Industries Ltd. | Treatment of neurodegenerative diseases with combination of laquinimod and fingolimod |
| WO2017019862A1 (en) * | 2015-07-30 | 2017-02-02 | Teva Pharmaceuticals Industries Ltd. | Combination formulation of laquinimod and glatiramer acetate with amino acids |
| JP2021521189A (ja) * | 2018-04-13 | 2021-08-26 | モデハイ シェヴィオンCHEVION, Mordechai | 脱髄の治療のための組成物及び方法 |
| AU2020408179A1 (en) | 2019-12-19 | 2022-06-30 | Active Biotech Ab | Compounds for treatment of eye diseases associated with excessive vascularisation |
| KR102350943B1 (ko) * | 2021-07-12 | 2022-01-14 | 주식회사 바움디자인시스템즈 | 집적 회로에 대한 소비 전력을 예측하는 방법 및 이를 수행하는 소비 전력 예측 시스템 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002076503A1 (en) * | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| US20070244056A1 (en) * | 2004-03-03 | 2007-10-18 | Liat Hayardeny | Combination Therapy With Glatiramer Acetate and Riluzole |
| WO2007146248A2 (en) * | 2006-06-12 | 2007-12-21 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
| ES2329327B1 (es) * | 2008-03-19 | 2010-09-17 | Proyecto De Biomedicina Cima, S.L. | Combinaciones sinergicas de 5'-metiltioadenosina. |
| UA104005C2 (ru) * | 2008-09-03 | 2013-12-25 | Тева Фармасьютикл Индастриз, Лтд. | 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции |
| TW201014605A (en) * | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
| WO2010070449A2 (en) * | 2008-12-17 | 2010-06-24 | Actavis Group Ptc Ehf | Highly pure laquinimod or a pharmaceutically acceptable salt thereof |
| KR20120037477A (ko) * | 2009-06-19 | 2012-04-19 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드를 이용한 다발경화증의 치료 |
| RS55071B1 (sr) * | 2009-08-10 | 2016-12-30 | Teva Pharma | Tretman poremećaja koji su u vezi sa bdnf primenom lakvinimoda |
| TW201127386A (en) * | 2009-10-27 | 2011-08-16 | Wyeth Llc | Bazedoxifene formulations with antioxidants |
| WO2011086470A1 (en) * | 2010-01-13 | 2011-07-21 | Ramot At Tel-Aviv University Ltd | Treatment of multiple sclerosis |
-
2012
- 2012-07-27 WO PCT/US2012/048684 patent/WO2013016684A1/en active Application Filing
- 2012-07-27 IN IN333MUN2014 patent/IN2014MN00333A/en unknown
- 2012-07-27 JP JP2014523092A patent/JP2014521658A/ja not_active Withdrawn
- 2012-07-27 EA EA201490377A patent/EA201490377A1/ru unknown
- 2012-07-27 BR BR112014002095A patent/BR112014002095A2/pt not_active IP Right Cessation
- 2012-07-27 EP EP12817089.1A patent/EP2736335A4/en not_active Withdrawn
- 2012-07-27 KR KR1020147005638A patent/KR20140054166A/ko not_active Application Discontinuation
- 2012-07-27 CN CN201610302142.2A patent/CN105944081A/zh active Pending
- 2012-07-27 PE PE2014000132A patent/PE20142319A1/es not_active Application Discontinuation
- 2012-07-27 CA CA2843433A patent/CA2843433A1/en not_active Abandoned
- 2012-07-27 SG SG10201606191PA patent/SG10201606191PA/en unknown
- 2012-07-27 US US13/560,851 patent/US20130029916A1/en not_active Abandoned
- 2012-07-27 AU AU2012286699A patent/AU2012286699A1/en not_active Abandoned
- 2012-07-27 CN CN201280043755.9A patent/CN103781354A/zh active Pending
- 2012-07-27 MX MX2014001050A patent/MX2014001050A/es unknown
- 2012-10-01 UY UY0001034358A patent/UY34358A/es not_active Application Discontinuation
-
2014
- 2014-01-28 CL CL2014000209A patent/CL2014000209A1/es unknown
- 2014-02-21 ZA ZA2014/01371A patent/ZA201401371B/en unknown
- 2014-11-21 HK HK14111812.7A patent/HK1198279A1/xx unknown
-
2015
- 2015-07-16 US US14/801,595 patent/US20160038532A1/en not_active Abandoned
-
2016
- 2016-05-06 US US15/148,074 patent/US20160361352A1/en not_active Abandoned
- 2016-07-11 AU AU2016204777A patent/AU2016204777A1/en not_active Abandoned
- 2016-08-24 CL CL2016002132A patent/CL2016002132A1/es unknown
- 2016-11-29 JP JP2016230818A patent/JP2017081930A/ja not_active Withdrawn
- 2016-12-22 HK HK16114575A patent/HK1226940A1/zh unknown
-
2017
- 2017-03-27 IL IL251397A patent/IL251397A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN105944081A (zh) | 2016-09-21 |
| EP2736335A1 (en) | 2014-06-04 |
| US20160361352A1 (en) | 2016-12-15 |
| MX2014001050A (es) | 2014-04-14 |
| US20160038532A1 (en) | 2016-02-11 |
| CN103781354A (zh) | 2014-05-07 |
| ZA201401371B (en) | 2015-08-26 |
| IL251397A0 (en) | 2017-05-29 |
| EA201490377A1 (ru) | 2014-11-28 |
| SG10201606191PA (en) | 2016-09-29 |
| PE20142319A1 (es) | 2015-01-24 |
| CA2843433A1 (en) | 2013-01-31 |
| KR20140054166A (ko) | 2014-05-08 |
| WO2013016684A1 (en) | 2013-01-31 |
| AU2012286699A1 (en) | 2014-03-13 |
| CL2014000209A1 (es) | 2014-08-22 |
| IN2014MN00333A (es) | 2015-09-25 |
| BR112014002095A2 (pt) | 2017-02-21 |
| AU2016204777A1 (en) | 2016-07-28 |
| US20130029916A1 (en) | 2013-01-31 |
| UY34358A (es) | 2014-02-28 |
| JP2017081930A (ja) | 2017-05-18 |
| CL2016002132A1 (es) | 2017-06-09 |
| JP2014521658A (ja) | 2014-08-28 |
| EP2736335A4 (en) | 2015-01-07 |
| HK1226940A1 (zh) | 2017-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL251397A0 (en) | Treatment of multiple sclerosis by administering a combination of laquinimod and glatiramer acetate | |
| HK1199820A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and fingolimod | |
| IL252699A0 (en) | Use of lequinimod to treat multiple sclerosis | |
| HK1198278A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and interferon beta | |
| HK1205941A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate | |
| HK1198631A1 (en) | Prevention and treatment of ocular conditions | |
| LT3378862T (lt) | Dihidropirimidinoizochinolinonai ir jų farmacinės kompozicijos, skirti išsėtinės sklerozės gydymui | |
| HK1209672A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and fampridine | |
| ZA201402820B (en) | Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof | |
| EP2726079A4 (en) | METHOD OF ADMINISTRATION AND TREATMENT | |
| ZA201408062B (en) | Compositions and methods for the treatment of multiple sclerosis | |
| EP2726154A4 (en) | PREVENTION AND TREATMENT OF ACUTE INFLAMMATORY CONDITIONS | |
| EP2670406A4 (en) | THERAPY COMBINED WITH INTERFERON AND ANDROGRAPHOLIDES FOR MULTIPLE SCLEROSIS | |
| AU2011902394A0 (en) | Prevention and treatment of acute inflammatory conditions |